Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

roxadustat

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

- PMLiVE

FDA investigates safety of Novartis’ MS drug

Agency to determine association between Gilenya and rare brain infection

- PMLiVE

AZ launches breast cancer video portal

Pharma company partners with oncology publisher for new HCP resource

- PMLiVE

FDA turns down Otsuka’s kidney disease candidate

Requests additional information for tolvaptan

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

- PMLiVE

AZ adds to pipeline again with Amplimmune buy

Pharma company pays $500m via its MedImmune subsidiary for the small US biotech

- PMLiVE

Novartis orphan drug wins ‘breakthrough’ status from FDA

Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

Bayer symbol

Bayer moves closer to US approval of PAH drug riociguat

FDA panel votes unanimously in favour of hypertension treatment

- PMLiVE

FDA panel turns down Otsuka’s drug for rare kidney disease

Unable to recommend expanded use of tolvaptan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links